A groundbreaking clinical trial presented at the prestigious ESC Congress 2026 has introduced a significant paradigm shift in how physicians might approach the prevention of heart attacks and strokes. The CorCal Outcomes trial revealed that using coronary artery calcium (CAC) scans to guide statin therapy decisions yielded the same observed rate of major cardiovascular events as traditional risk assessment methods. However, this was achieved despite substantially fewer recommendations for patients to begin statin therapy, and a remarkable improvement in patient adherence to prescribed medications among those advised to take statins based on scan results. These findings, unveiled during a high-profile Hot Line session, suggest that while direct visualization of arterial disease may not necessarily increase the number of patients receiving statin recommendations, it could profoundly influence who receives them and, critically, whether they consistently adhere to treatment.
The Enduring Challenge of Cardiovascular Disease Prevention
Cardiovascular disease (CVD) continues to be the leading cause of mortality and morbidity globally, with atherosclerotic cardiovascular disease (ASCVD) accounting for a substantial portion of this burden. ASCVD arises from the gradual buildup of fatty deposits, known as plaque, within arterial walls. This process, termed atherosclerosis, narrows arteries, impeding blood flow and escalating the risk of catastrophic events such as heart attacks (myocardial infarctions) and strokes (cerebrovascular accidents). Conditions like coronary artery disease and ischemic stroke are prominent manifestations of this insidious disease process.
The development of ASCVD is intricately linked to a confluence of modifiable risk factors. These include lifestyle elements such as smoking, dietary habits contributing to high blood pressure and elevated cholesterol levels, and metabolic conditions like diabetes. Medical professionals have long utilized these established risk factors to estimate an individual’s probability of experiencing a cardiovascular event, thereby informing decisions regarding the initiation of preventive therapies.
Statins, a class of lipid-lowering medications, have emerged as a cornerstone of ASCVD prevention strategies. Their primary mechanism of action involves reducing the levels of low-density lipoprotein cholesterol (LDL-C), colloquially known as "bad cholesterol," which is a key driver of plaque formation. By effectively lowering LDL-C, statins have been demonstrably proven to reduce the incidence of serious cardiovascular complications.
Despite the efficacy of statins, a persistent and vexing challenge remains: accurately identifying which patients will derive the greatest benefit from these medications. A significant proportion of individuals who ultimately suffer a cardiovascular event do not present with a high-risk profile according to conventional screening methodologies. This diagnostic gap means that potentially life-saving interventions are not being offered to a subset of high-risk individuals, or conversely, that statins might be prescribed to individuals who would not have benefited significantly.
Dr. Joseph B. Muhlestein of the Intermountain Medical Center in Murray, USA, and Principal Investigator of the CorCal Outcomes trial, articulated this critical dilemma: "For far too many patients, the first symptom of ASCVD is a heart attack. Statins have been shown to be highly effective in the prevention of ASCVD; however, there is a major gap in risk assessment, statin initiation, and statin persistence." He further elaborated that many first-time heart attack sufferers, particularly younger adults, would not have previously been classified as having sufficient cardiovascular risk to warrant statin treatment. This observation spurred the investigation into whether direct visualization of arterial disease, rather than solely relying on risk factor calculators, could offer a more precise approach.
The CorCal Outcomes Trial: A Comparative Analysis
The CorCal Outcomes trial was meticulously designed to compare two distinct strategies for guiding statin therapy recommendations in individuals without pre-existing ASCVD or diabetes, and who had not previously been treated with statins. The study enrolled 5,772 participants from the Canyons and Desert regions of Intermountain Health Care in the United States. The cohort was representative, with an average age of 64 years and a slight female majority (51%).
The two arms of the trial employed different methodologies for risk assessment:
-
Traditional Risk Assessment: This approach utilized the Pooled Cohort Equations (PCE). These widely adopted algorithms estimate a 10-year risk of atherosclerotic cardiovascular disease events by integrating a patient’s age, sex, race, cholesterol levels (total and HDL), blood pressure, smoking status, and history of diabetes. Based on the calculated risk score, physicians would then make a recommendation regarding statin initiation, often adhering to established clinical guidelines that define thresholds for preventive therapy.
-
Coronary Artery Calcium (CAC) Scoring: This method involved a non-invasive computed tomography (CT) scan of the heart to quantify the amount of calcium deposited within the coronary arteries. Calcium is a component of atherosclerotic plaque, and its presence and quantity serve as a direct, albeit indirect, marker of underlying coronary artery disease. A higher CAC score indicates a greater burden of atherosclerosis. Unlike risk calculators that predict future events based on current risk factors, CAC scoring provides evidence of existing disease within the arteries, regardless of whether symptoms are present.
Participants were randomly assigned in a 1:1 ratio to either the traditional risk assessment group or the CAC scoring group. Crucially, both patients and their physicians were informed of the treatment recommendations generated by the study protocol. However, the ultimate decision to initiate statin therapy rested with the patient and their physician, allowing for real-world clinical decision-making to play a role. The primary endpoint of the trial was the occurrence of major adverse cardiovascular events (MACE), defined as a composite of all-cause mortality, myocardial infarction, stroke, and arterial revascularization procedures (such as angioplasty or bypass surgery) aimed at restoring blood flow to narrowed or blocked arteries.
Striking Similarities in Outcomes, Profound Differences in Recommendations
After an average follow-up period of 4.2 years, the CorCal Outcomes trial delivered a surprising and nuanced set of results. The observed rates of major cardiovascular events were virtually identical between the two groups. In both the traditional risk assessment arm and the CAC scoring arm, 2.7% of patients experienced at least one of the MACE endpoints. Statistical analysis confirmed a near-identical estimated relative risk over time, with a hazard ratio of 0.99 (95% confidence interval: 0.71 to 1.38). The noninferiority p-value was 0.045, which, while close, did not meet the pre-specified statistical threshold for demonstrating that the CAC scan approach was not meaningfully worse than conventional risk assessment. This means that while the CAC approach did not prove to be definitively superior in preventing events, it certainly did not prove to be inferior.
However, the starkest contrast between the two strategies emerged in the number of statin recommendations issued. Patients whose treatment decisions were guided by traditional risk scores received recommendations to initiate statin therapy more than three times as frequently as those whose decisions were informed by CAC scan results. This finding underscores a potential over-reliance on traditional risk factors, possibly leading to a broader application of statin therapy than might be strictly necessary for some individuals. Despite this significant divergence in the frequency of statin initiation, the fact that both groups experienced the same incidence of major cardiovascular events during the study period raises important questions about the optimal threshold for statin prescription.
A Game-Changer in Statin Adherence
Perhaps the most compelling and unexpected finding of the CorCal Outcomes trial was the profound difference in patient adherence to statin medication. Among the patients who were advised to take statins, those whose recommendations were based on CAC scan results demonstrated significantly higher rates of adherence compared to their counterparts in the traditional risk assessment group. The adherence rates were 62% for the CAC-guided group versus a mere 23% for the traditional risk assessment group. This translates to patients recommended statins based on the visible evidence of calcium buildup in their arteries being approximately 2.7 times more likely to consistently take their prescribed medication.
Researchers hypothesize that the direct visualization of disease within their own arteries may serve as a powerful motivator for patients to engage more actively in their preventive healthcare. Seeing tangible evidence of atherosclerosis could foster a greater sense of urgency and personal responsibility for managing their cardiovascular health. While the trial did not definitively establish the underlying reasons for this dramatic difference in adherence, the implication is substantial: CAC scoring might not only refine who is recommended statins but also significantly improve the effectiveness of those recommendations by ensuring patients actually take the medication as prescribed.
Implications for the Future of Heart Disease Prevention
The findings from the CorCal Outcomes trial carry significant implications for the future of cardiovascular disease prevention, even as researchers emphasize that the study could not definitively prove the superiority of CAC scan-guided treatment in terms of cardiovascular protection. A key limitation acknowledged by the investigators was that the actual number of major cardiovascular events observed was lower than anticipated. This reduction in event rates diminished the statistical power of the study to detect a meaningful difference between the two approaches.
Dr. Muhlestein articulated this point clearly: "The power of the study to detect a difference was reduced by the lower-than-expected event rates and we did not demonstrate noninferiority between the groups." However, he also highlighted the trial’s value in generating crucial hypotheses: "The study did provide important hypothesis-generating insights into the efficiency of statin initiation and adherence when decisions are based on CAC scoring. Taken together, our data could be used to plan an additional well-powered randomized trial comparing CAC with current risk factor-based algorithms."
The data generated by CorCal Outcomes is expected to inform the design of future, larger-scale randomized controlled trials that can more definitively assess whether coronary calcium scans can enhance the efficiency of statin prescribing without compromising cardiovascular protection. The potential to improve adherence through direct visualization of disease could translate into more effective long-term prevention strategies.
It is noteworthy that current European guidelines already recognize the evolving role of CAC scoring in cardiovascular risk assessment. The 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidemias suggests considering elevated coronary calcium scores as an additional factor in risk assessment, particularly for individuals at moderate cardiovascular risk or those whose calculated risk falls near the threshold for preventive medication. In cases where the need for statin therapy is uncertain, the presence of demonstrable calcium buildup can empower physicians to make more informed and personalized treatment decisions.
The CorCal Outcomes trial adds a crucial new dimension to this ongoing discussion, suggesting that the impact of heart scans may extend beyond risk stratification to influence patient engagement and treatment adherence. Whether this enhanced adherence ultimately leads to demonstrably better long-term cardiovascular outcomes remains a pivotal question that future research endeavors will undoubtedly seek to answer, potentially reshaping how we approach the prevention of heart attacks and strokes for millions worldwide.
